Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Karyopharm Therapeutics (KPTI) EPS (Weighted Average and Diluted) (2020 - 2025)

Karyopharm Therapeutics' EPS (Weighted Average and Diluted) history spans 6 years, with the latest figure at -$7.0 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 94.44% year-over-year to -$7.0; the TTM value through Dec 2025 reached -$17.91, down 17.29%, while the annual FY2025 figure was -$17.93, 28.07% down from the prior year.
  • EPS (Weighted Average and Diluted) reached -$7.0 in Q4 2025 per KPTI's latest filing, down from -$3.82 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.52 in Q4 2021 to a low of -$17.9 in Q4 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$2.89, with a median of -$0.71 recorded in 2021.
  • Peak YoY movement for EPS (Weighted Average and Diluted): soared 691.55% in 2021, then crashed 4161.9% in 2023.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.52 in 2021, then crashed by 180.77% to -$0.42 in 2022, then plummeted by 4161.9% to -$17.9 in 2023, then soared by 79.89% to -$3.6 in 2024, then crashed by 94.44% to -$7.0 in 2025.
  • Per Business Quant, the three most recent readings for KPTI's EPS (Weighted Average and Diluted) are -$7.0 (Q4 2025), -$3.82 (Q3 2025), and -$4.32 (Q2 2025).